Posts Tagged ‘Investing’
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
21 Mar 2023
Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week.
Nasodine composition patent accepted in Australia
14 Nov 2022
Firebrick Pharma Limited is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray has been accepted in Australia.
Nasodine Phase 3 common cold trial underway
03 May 2022
Firebrick Pharma is pleased to announce that the first patient has been recruited into its confirmatory Phase 3 trial for Nasodine® Nasal Spray (“Nasodine”) as a treatment for the common cold. The randomised controlled Phase 3 trial expects to recruit up to 450 adult subjects with early cold symptoms to achieve a target treatment population…